⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449360 | 0.70 | — | — | |
| SCHEMBL449593 | 0.67 | — | — | |
| SCHEMBL9588153 | 0.67 | CYP19A1 (0.31) | — | |
| SCHEMBL11546949 | 0.64 | — | — | |
| SCHEMBL1259706 | 0.60 | — | — | |
| SCHEMBL21650075 | 0.56 | RAB9A (0.33) | — | |
| SCHEMBL651428 | 0.51 | MEN1 (0.75) | — | |
| SCHEMBL8688932 | 0.50 | TSHR (0.55) | — | |
| SCHEMBL212845 | 0.50 | CYP19A1 (0.81) | — | |
| SCHEMBL1194020 | 0.49 | TSHR (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677810-A | Double-stranded oligonucleotide, composition containing double-stranded oligonucleotide, conjugate, preparation method and application | 苏州瑞博生物技术股份有限公司 | 2023-02-03 | — | — | CN | claimed |
| US-9884886-B2 | Disulfide masked prodrug compositions and methods | MERCK SHARP & DOHME (US) | 2018-02-06 | — | — | US | claimed |
| WO-2024123993-A1 | SELECTIVE APOPTOSIS-INDUCING METHODS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-06-13 | — | — | WO | disclosed |
| CN-111849912-B | Method for activating T cells using inducible chimeric polypeptides | 贝里坤制药股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117402829-A | Dual control for therapeutic cell activation or elimination | 贝里坤制药股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-11839647-B2 | Methods for inducing partial apoptosis using caspase polypeptides | BELLICUM PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230270831-A1 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | BAYLOR COLLEGE OF MEDICINE | 2023-08-31 | — | — | US | disclosed |
| EP-4219544-A1 | T-CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum (NL) | 2023-08-02 | — | — | EP | disclosed |
| EP-4201955-A1 | T-CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum (NL) | 2023-06-28 | — | — | EP | disclosed |
| US-20230065562-A1 | DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-03-02 | — | — | US | disclosed |
| CN-115677810-A | Double-stranded oligonucleotide, composition containing double-stranded oligonucleotide, conjugate, preparation method and application | 苏州瑞博生物技术股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-1913011-A2 | OLIGONUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | Alnylam Pharmaceuticals Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1828215-A2 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | Alnylam Pharmaceuticals Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070197460-A1 | RNAI INHIBITION OF INFLUENZA VIRUS REPLICATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2007053696-A2 | RNAI INHIBITION OF INFLUENZA VIRUS REPLICATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2006112872-A2 | OLIGONUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006093526-A2 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| CN-1088202-A | Benzoglyoxaline contains pharmaceutical composition of these compounds and preparation method thereof | THOMAE GMBH DR K (DE) | 1994-06-22 | — | — | CN | disclosed |